Donepezil Attenuate Postoperative Cognitive Dysfunction
NCT02927522 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550
Last updated 2020-01-30
Summary
Postoperative cognitive dysfunction (POCD) occurs mainly in aged patients. POCD may increase the mortality and morbidity. However, the mechanism of POCD is not clear yet and no effective therapy method was proved. According to our previous study, the central cholinergic system impaired by the anesthesia and surgery play a very important role in the POCD and donepezil an acetylcholinesterase inhibitor can prevent the POCD after isoflurane anesthesia in aged mice. Donepezil is a commercial medicine used for the Alzheimer Disease, which is tolerable and has minimal adverse events. In present study a multi-center randomized case control study was conducted and we hypothesized that donepezil attenuate the POCD.
Conditions
- Osteoarthritis
- Femoral Head Necrosis
- Rheumatoid Arthritis
Interventions
- DRUG
-
Donepezil
Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
- DRUG
-
Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
Sponsors & Collaborators
-
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
collaborator OTHER -
RenJi Hospital
lead OTHER
Principal Investigators
-
Diansan Su, M.D., Ph.D. · RenJi Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-09-01
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- China
Study Locations
More Related Trials
-
The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.
NCT03907371 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients
NCT02648906 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil
NCT01024660 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
NCT02660983 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment
NCT00530478 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial
NCT01633593 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment
NCT02982603 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients
NCT00480870 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).
NCT02695004 ·Status: COMPLETED ·Phase: PHASE1
-
Brain Imaging and Mental Disorders of Aging Intervention
NCT00267163 ·Status: COMPLETED ·Phase: PHASE4
-
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
NCT03349320 ·Status: COMPLETED
-
Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease
NCT05114499 ·Status: UNKNOWN
-
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-
NCT01129596 ·Status: COMPLETED
-
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
NCT00165737 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease
NCT03810794 ·Status: RECRUITING ·Phase: NA
-
Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial
NCT00196690 ·Status: COMPLETED ·Phase: PHASE4
-
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
NCT02337907 ·Status: COMPLETED ·Phase: PHASE2
-
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
NCT02162251 ·Status: COMPLETED
-
Donepezil to Treat Dementia in Parkinson's Disease
NCT00030979 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240 ·Status: COMPLETED ·Phase: PHASE1
-
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
NCT00293176 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain
NCT05003063 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease
NCT01251718 ·Status: COMPLETED
-
Zydena on Cognitive Function of Alzheimer's Disease Patients
NCT01940952 ·Status: UNKNOWN ·Phase: PHASE3
-
Memory and Mental Health in Aging
NCT02988908 ·Status: COMPLETED ·Phase: PHASE4